INC Research Reaches Major Trusted Process® Milestone with 500th QuickStart® Camp

Raleigh, N.C., Dec. 13, 2012 - INC Research, LLC, a therapeutically focused clinical research organization (CRO), today announced it has reached a major milestone with its metrics-driven clinical trial outsourcing methodology known as the Trusted Process®, completing its 500th QuickStart® Camp this week.  Designed to align expectations and build study ownership across the entire project team from the onset of a study, INC Research's QuickStart® Camp is a unique, week-long collaborative meeting featuring a series of moderated gatherings to drive accurate study planning and conduct proactive risk management.  The approach brings together the customer team, vendors and the internal INC Research team to proactively work through their drug development programs to reduce variability and increase predictability in trial outcomes.

"Through 500 QuickStart® Camps we have continually evolved our process to deliver the most reliable, repeatable and efficient process in the industry," said Jeff Kueffer, Senior Vice President, Operations Management and one of the chief architects of the Trusted Process®. "It's extremely gratifying to have reached this milestone. When you deliver what you say you're going to deliver, consistently over a long period of time, customers tend to come back. To be able to tell a customer that we can guarantee quality data and a significantly faster start-up time, and know we can deliver on that promise without question, not only gives them a degree of confidence that their project will be completed faster, but also a sense of trust in  the results they obtain. "

Better by Design
QuickStart® was developed from a systems engineering and fundamental project management perspective that focused specifically on introducing efficiencies into the study start-up process. Customers using INC Research's Trusted Process® report faster study start-up times (four weeks faster than the industry average), completing patient enrollment as planned and experiencing database lock one week faster than the industry average.

Customers have fully embraced the approach. One customer recently noted, "QuickStart® took a month's work and compressed it into a week. I'm thrilled with the speed, but even more impressed with the high quality. INC Research married both." Other customers have insisted they will never start a project any other way.

The successful early implementation of QuickStart® was in turn the genesis for the development of INC's Trusted Process® methodology.  Since 2006, INC Research has conducted all trials using its Trusted Process® methodology - a proprietary process-oriented trial management approach that produces actionable data on time and on budget. QuickStart® is one of four phases in INC Research's Trusted Process clinical trials methodology. Each phase - PlanActivation®, QuickStart®, ProgramAccelerate® and QualityFinish® - is specifically designed to maintain high standards while driving efficiency throughout the process, which leads to a high level of confidence to make informed decisions about study data and analysis.

For more information about the benefits of process-driven clinical research, please view our video or download our Trusted Process® brochure.

About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical developmentprograms of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit or follow us at @inc_research.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.